127 related articles for article (PubMed ID: 36241000)
21. Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia.
Cao T; Ye Y; Liao H; Shuai X; Jin Y; Su J; Zheng Q
Medicine (Baltimore); 2019 Jun; 98(23):e15948. PubMed ID: 31169718
[TBL] [Abstract][Full Text] [Related]
22. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
23. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
Zhang Y; Saavedra E; Tang R; Gu Y; Lappin P; Trajkovic D; Liu SH; Smeal T; Fantin V; De Botton S; Legrand O; Delhommeau F; Pernasetti F; Louache F
Sci Rep; 2017 Aug; 7(1):7305. PubMed ID: 28779088
[TBL] [Abstract][Full Text] [Related]
24. The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia.
Cao T; Jiang N; Liao H; Shuai X; Su J; Zheng Q
Sci Rep; 2019 Aug; 9(1):12209. PubMed ID: 31434952
[TBL] [Abstract][Full Text] [Related]
25. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
26. [CXCR4: a new therapeutic target of the leukaemic cell? Role of the SDF-1/CXCR4 axis in acute myeloid leukaemia].
Tavernier E; Aanei C; Solly F; Flandrin-Gresta P; Campos L; Guyotat D
Bull Cancer; 2014 Jun; 101(6):593-604. PubMed ID: 24977448
[TBL] [Abstract][Full Text] [Related]
27. Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells.
Kalinkovich A; Tavor S; Avigdor A; Kahn J; Brill A; Petit I; Goichberg P; Tesio M; Netzer N; Naparstek E; Hardan I; Nagler A; Resnick I; Tsimanis A; Lapidot T
Cancer Res; 2006 Nov; 66(22):11013-20. PubMed ID: 17108140
[TBL] [Abstract][Full Text] [Related]
28. The role of polymorphisms of stromal-derived factor-1 and CXC receptor 4 in acute myeloid leukemia and leukemia cell dissemination.
Zheng Q; Shuai X; Ye Y; Jin Y; Jiang N; Chen X; Su J
Gene; 2016 Aug; 588(2):103-8. PubMed ID: 27154815
[TBL] [Abstract][Full Text] [Related]
29. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
30. The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
Abraham M; Klein S; Bulvik B; Wald H; Weiss ID; Olam D; Weiss L; Beider K; Eizenberg O; Wald O; Galun E; Avigdor A; Benjamini O; Nagler A; Pereg Y; Tavor S; Peled A
Leukemia; 2017 Nov; 31(11):2336-2346. PubMed ID: 28280274
[TBL] [Abstract][Full Text] [Related]
31. Self-Stimulated Photodynamic Nanoreactor in Combination with CXCR4 Antagonists for Antileukemia Therapy.
Zhang Y; Chen L; Fu T; Xu A; Li K; Hao K; Lyu J; Wang Z; Kong F
ACS Appl Mater Interfaces; 2024 May; 16(17):21610-21622. PubMed ID: 38647446
[TBL] [Abstract][Full Text] [Related]
32. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
[TBL] [Abstract][Full Text] [Related]
33. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.
Pan XQ; Zheng X; Shi G; Wang H; Ratnam M; Lee RJ
Blood; 2002 Jul; 100(2):594-602. PubMed ID: 12091353
[TBL] [Abstract][Full Text] [Related]
34. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
[TBL] [Abstract][Full Text] [Related]
35. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.
Habringer S; Lapa C; Herhaus P; Schottelius M; Istvanffy R; Steiger K; Slotta-Huspenina J; Schirbel A; Hänscheid H; Kircher S; Buck AK; Götze K; Vick B; Jeremias I; Schwaiger M; Peschel C; Oostendorp R; Wester HJ; Grigoleit GU; Keller U
Theranostics; 2018; 8(2):369-383. PubMed ID: 29290814
[TBL] [Abstract][Full Text] [Related]
36. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
[TBL] [Abstract][Full Text] [Related]
37. CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Nakamura N; Tomizawa D; Saito AM; Kiyokawa N; Horibe K; Nishinaka-Arai Y; Tokumasu M; Itoh H; Kamikubo Y; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Pediatr Blood Cancer; 2016 Aug; 63(8):1394-9. PubMed ID: 27135782
[TBL] [Abstract][Full Text] [Related]
38. Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells.
Lu Y; Wu J; Wu J; Gonit M; Yang X; Lee A; Xiang G; Li H; Liu S; Marcucci G; Ratnam M; Lee RJ
Mol Pharm; 2007; 4(5):707-12. PubMed ID: 17708654
[TBL] [Abstract][Full Text] [Related]
39. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
